Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy(697 views) Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2010 Apr; 16(4): 450-454.
Keywords: Activity, Combination Therapy, Interferon Beta, Multiple Sclerosis, Statin, Atorvastatin, Beta1a Interferon, Gadolinium, Antiinflammatory Agent, Beta Interferon, Contrast Medium, Diagnostic Agent, Heptanoic Acid Derivative, Pyrrole Derivative, Add On Therapy, Adult, Article, Blood Analysis, Cholesterol Blood Level, Clinical Article, Clinical Assessment, Clinical Trial, Contrast Enhancement, Controlled Clinical Trial, Controlled Study, Creatine Kinase Blood Level, Disease Course, Drug Efficacy, Drug Megadose, Drug Safety, Drug Tolerability, Expanded Disability Status Scale, Female, Human, Longitudinal Study, Low Drug Dose, Monotherapy, Muscle Cramp, Myalgia, Neuroimaging, Nuclear Magnetic Resonance Imaging, Outcome Assessment, Randomization, Randomized Controlled Trial, Relapse, Risk Assessment, Screening, Side Effect, Survival, Treatment Duration, Treatment Response, Chi Square Distribution, Drug Administration, Drug Combination, Hospitalization, Nonparametric Test, Prediction And Forecasting, Treatment Outcome, Anti-Inflammatory Agents, Chi-Square Distribution, Disability Evaluation, Drug Administration Schedule, Drug Therapy, Interferon-Beta, Longitudinal Studies, Relapsing-Remitting, Predictive Value Of Tests, Severity Of Illness Index, Statistics, Time Factors, Anti-Inflammatory Agents Administration, Dosage Adverse Effects Therapeutic Use, Contrast Media Diagnostic Use, Heptanoic Acids Administration, Interferon-Beta Administration, Relapsing-Remitting Diagnosis Drug Therapy, Pyrroles Administration, Interferon Beta-1a
Affiliations: *** IBB - CNR ***
Federico II University, Neurological Sciences Department, Naples, Italy
Hermitage Capodimonte, IDC, Naples, Italy
Biostructure and Bioimaging Institute, National Research Council, Naples, Italy
SDN, Foundation, Naples, Italy
Ospedale Moscati, Avellino, Italy
Second University of Naples, Neurology Department, Italy
Federico University, Neurological Sciences Department, Naples, Italy. robertalanzillo@libero.it
References: Not available.
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy